1. Home
  2. ANPA vs TCRX Comparison

ANPA vs TCRX Comparison

Compare ANPA & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rich Sparkle Holdings Limited Ordinary Shares

ANPA

Rich Sparkle Holdings Limited Ordinary Shares

HOLD

Current Price

$2.62

Market Cap

47.0M

Sector

N/A

ML Signal

HOLD

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$0.32

Market Cap

49.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANPA
TCRX
Founded
2016
2018
Country
Hong Kong
United States
Employees
32
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.0M
49.4M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
ANPA
TCRX
Price
$2.62
$0.32
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
49.0K
935.8K
Earning Date
02-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.28
EPS
N/A
N/A
Revenue
N/A
$10,325,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$19.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
266.65
52 Week Low
$2.81
$0.33
52 Week High
$180.64
$2.57

Technical Indicators

Market Signals
Indicator
ANPA
TCRX
Relative Strength Index (RSI) 27.32 17.58
Support Level N/A N/A
Resistance Level $4.59 $0.82
Average True Range (ATR) 0.34 0.05
MACD -0.12 -0.04
Stochastic Oscillator 2.41 1.88

Price Performance

Historical Comparison
ANPA
TCRX

About ANPA Rich Sparkle Holdings Limited Ordinary Shares

Rich Sparkle Holdings Ltd is a holding company conducting its operations as a professional specialist in the provision of financial printing services such as printing, typesetting and translation, advisory services including Environmental, Social and Governance (ESG) and internal control reporting services and other services including standalone annual general meeting and extraordinary general meeting supporting service and other standalone services, through its sole operating subsidiary in Hong Kong. Its segments include Financial printing services such as printing, typesetting and translation, Advisory services including Environmental, Social and Governance Report and Other services.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: